T. Rowe Price Associates
CLCD

T. Rowe Price Associates’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

T. Rowe Price Associates’s Portfolio CLCD Stock Details CLCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,330,434
Closed -$84.8M – 2627
2016
Q4 		$84.8M Sell
2,330,434
-155,840
-6% -$5.51M 0.02% 645
2016
Q3 		$94.9M Buy
2,486,274
+1,158,959
+87% +$17.1M 0.02% 590
2016
Q2 		$10.8M Sell
1,327,315
-800
-0.1% -$5.37K ﹤0.01% 1276
2016
Q1 		$8.23M Sell
1,328,115
-19,780
-1% -$124K ﹤0.01% 1312
2015
Q4 		$11.3M Sell
1,347,895
-7,940
-0.6% -$41.8K ﹤0.01% 1256
2015
Q3 		$5.25M Buy
1,355,835
+82,245
+6% +$608K ﹤0.01% 1428
2015
Q2 		$11.3M Buy
+1,273,590
New +$10.9M ﹤0.01% 1315

Other funds holding CLCD

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

T. Rowe Price Associates's CLCD Position: Q1 2017 in Review

T. Rowe Price Associates sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q1 2017, closing a stake of 2,330,434 shares — an estimated $84.8M sold.

T. Rowe Price Associates first reported a position in CLCD in Q2 2015 and held it in 7 quarters. The position peaked at $94.9M in Q3 2016. 1 fund tracked by Wall St. Rank holds CLCD as of Q1 2017.

  • T. Rowe Price Associates reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • T. Rowe Price Associates sold 2,330,434 CoLucid Pharmaceuticals, Inc. shares in Q1 2017, an estimated $84.8M.
  • T. Rowe Price Associates first reported a position in CoLucid Pharmaceuticals, Inc. in Q2 2015 and held it in 7 quarters.
  • T. Rowe Price Associates's CoLucid Pharmaceuticals, Inc. position peaked at $94.9M in Q3 2016.
  • 1 fund tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q1 2017.

Based on T. Rowe Price Associates's 13F filing for Q1 2017, filed 15 May 2017.